Although parathyroid hormone (PTH) has long been known to act as a bone anabolic agent when administered intermittently, the exact underlying mechanisms remain largely unknown. Amphiregulin (AREG), a ligand of the epidermal growth factor receptor, has been identified to be a PTH target gene in vitro and in vivo. Here, we used female global AREG knockout (AREG-KO) mice to explore the role of AREG in mediating the bone anabolic effects of PTH. AREG-KO mice were characterized by unchanged distal femoral cancellous bone mass and only subtle decreases in bone mineral density (BMD) and cortical thickness at the femoral midshaft at 3 and 8 months of age, relative to wildtype controls. AREG deficiency was associated with complex changes in the mRNA expression of other EGFR ligands in femoral cancellous bone osteoblasts in situ in 3-week-old mice. To examine the bone anabolic effects of PTH in the absence and presence of AREG, we injected 3-month-old AREG-KO females and wildtype control littermates with 80 mg/kg PTH or vehicle 5 times per week over 4 weeks. Intermittent PTH treatment of AREG-KO mice led to increases in femoral trabecular and cortical BMD, cortical thickness, endocortical and periosteal bone formation, cancellous bone formation rate, and serum osteocalcin, comparable to those observed in wildtype control mice. In conclusion, our data indicate that the bone anabolic effects of PTH do not require AREG, at least in 3-month-old female mice.
Introduction
Parathyroid hormone (PTH) is the main short-term hormonal regulator of bone remodeling and calcium homeostasis (Poole and Reeve, 2005) . It is secreted by the parathyroid glands in response to low extracellular ionized calcium levels. PTH binds at its target cells to the PTH receptor, a G-protein-coupled receptor, and activates several intracellular signaling pathways (Swarthout et al., 2002) . PTH acts directly on the bone to initiate bone resorption and on the kidneys to stimulate tubular calcium re-absorption and synthesis of 1,25-dihydroxyvitamin D 3 , which then enhances the calcium uptake in the small intestine. Paradoxically, in addition to this classical bone catabolic action, PTH can also act as a bone anabolic agent depending on the way of administration. While continuous infusion of PTH causes bone loss, intermittent PTH injections stimulate bone formation and significantly increase bone mineral density (BMD) (Tam et al., 1982; Hock et al., 1988; Poole and Reeve, 2005) . Teriparatide, a recombinant 1e34 peptide of PTH, is currently used successfully as a treatment for osteoporosis (Partridge et al., 2006) .
Several pathways and molecules have been identified to play an important role in mediating this bone anabolic effect of PTH, including insulin-like growth factor-1 (Miyakoshi et al., 2001 ), c-fos (Demiralp et al., 2002) , interleukin-18 (Raggatt et al., 2008) , betaarrestin 2 (Bouxsein et al., 2005) and sclerostin (Kramer et al., 2010) . Additionally, microarray analyses were used to assess PTHregulated genes in bone (Qin et al., 2003; von Stechow et al., 2004) , and to compare gene expression profiles between continuous and intermittent PTH treatment (Onyia et al., 2005) . It has been confirmed in several studies that not only genes associated with bone formation are required for the full anabolic effect of PTH, but also genes related to bone resorption and osteoclastogenesis (Koh et al., 2005; Li et al., 2007a Li et al., , 2007b Tamasi et al., 2013) .
The epidermal growth factor receptor (EGFR, ERBB1, HER1) and its ligands have been reported to play an important role in bone biology and in mediating the anabolic actions of intermittent PTH (Schneider et al., 2009b) . Microarray analysis identified amphiregulin (Areg), a ligand of the EGFR (Berasain and Avila, 2014; Schneider and Wolf, 2009) , as a PTH-regulated gene in rat UMR 106-01 osteoblastic cells (Qin et al., 2003) . Additional studies showed an increase of Areg mRNA levels in PTH-treated mouse MC3T3 cells and in rat calvarial primary osteoblastic cells, as well as in the femora of rats injected with PTH, confirming that Areg is a PTH target gene in vitro and in vivo (Qin et al., 2005) . Areg is also a target gene for other bone anabolic factors, such as 1,25-dihydroxyvitamin D 3 and PGE 2 . It stimulates proliferation and prevents differentiation and mineralization in osteoblastic cells, and female mice lacking AREG have been reported to have less trabecular bone than their control littermates at an age of four weeks (Qin et al., 2005) .
Recently, it was shown that PTH-mediated release of AREG in osteoblastic cells promotes the migration of mesenchymal progenitors to the bone surface via PI3K/Akt and p38MAPK pathways (Zhu et al., 2012) . Furthermore, the anabolic effect of PTH was blunted in mice with impaired EGFR activity in osteoblasts (Zhu et al., 2012) . Thus, AREG seems to be the major EGFR ligand mediating the bone anabolic effect of PTH. However, it is still unclear whether these putative effects of AREG are an essential component of PTH's bone anabolic actions. In addition, the role of AREG in bone development and homeostasis in vivo has been only superficially investigated. Hence, to clarify to which extent AREG is required for the full anabolic action of PTH, global AREG-KO mice at an age of 12 weeks and their control littermates were intermittently injected with PTH, and the bone phenotype of these mice was evaluated in detail. We found that AREG deficient mice have only subtle changes in their skeletal phenotype, and that AREG is not essential for the bone anabolic actions of PTH.
Material and methods

Animals
Global AREG knockout (AREG-KO) mice (Luetteke et al., 1999) were obtained from The Mutant Mouse Regional Resource Center (MMRRC) Repository at the University of North Carolina, USA. The animals were maintained in a 129/C57BL/6 mixed background under specified pathogen free conditions in a closed barrier facility and had free access to a standard rodent diet (V1534; Ssniff, Soest, Germany) and tap water. Genotyping was performed using the primers AregDel#1 (5 0 CTT TCC AGC TTT CTC CAC CTC AAG 3 0 ), AregDel#2 (5 0 ACA GTA ACC TCT GTT GCA TGC CAC 3 0 ) and AregDel#3 (5 0 CTG CAC GAG ACT AGT GAG ACG TGC 3 0 ). Heterozygous AREG knockout mice were intercrossed to obtain homozygous knockout mice and wildtype (WT) control littermates. Only female mice were used for phenotyping of AREG-KO mice and PTH treatment. Before killing the animals, spontaneous urine was collected for measurement of bone resorption parameters. All experiments were approved by the Institutional Committee on Animal Care and carried out with permission from the responsible veterinary authority.
PTH treatment of mice
AREG-KO females at an age of 12 weeks and their WT littermates received either 80 mg/kg body weight (1e34) PTH (Bachem, Weil am Rhein, Germany) or vehicle (physiological saline) by subcutaneous injection once daily for five days per week over a period of four weeks. All mice were subcutaneously injected with alizarin complexone (30 mg/kg body weight) once at the beginning of the experiment and with calcein (20 mg/kg body weight) on days 4 and 2 before necropsy. Both fluorochromes were purchased from SigmaeAldrich (Schnelldorf, Germany).
Serum and tissue collection
Blood samples were taken from the retroorbital plexus of anesthetized mice, serum was obtained by centrifugation and stored at À80 C. The femora were removed and further processed as indicated below.
m-CT analysis
In order to assess the trabecular and cortical bone microarchitecture of the left femur, quantitative microcomputed tomography was performed according to recent standards (Bouxsein et al., 2010) , using a Scanco mCT35 (Scanco Medical AG, Brüttisellen, Switzerland) .
In the femoral mid-diaphysis, a region of 0.8 mm in length, covering a total of 115 slices was analyzed. Voxel size was 7 mm (isotropic). For analysis of the distal femoral metaphysis, we used 170 slices starting 0.49 mm proximal from the growth plate. Image acquisition was performed at 70 kV and 114 mA with an angular increment of 0.18 between projections, and an isotropic voxel size of 3.5 mm. The grayscale images obtained were processed using a 3D Gaussian filter with s ¼ 0.8 to remove noise. A threshold of 361 mg hydroxyapatite/cm 3 ; was used to distinguish bone from the background (corresponding to a linear attenuation of m ¼ 1.6).
Unbiased 3D microstructural properties of cortical and trabecular bone were calculated using methods based on distance transformation of the binarized images as described previously (Schneider et al., 2012) . Cross-sectional and 3D images were constructed using the volume rendering software Drishti (Limaye, 2012) .
Bone histology and histomorphometry
Histological processing of the femurs and cancellous as well as cortical bone histomorphometry were performed as described previously (Erben, 1996; Reim et al., 2008; Schneider et al., 2009a) . The right femur was fixed in 4%PFA in PBS at 4 C for 24 h and washed with PBS for 24 h. The femur was cut in half and the distal part was dehydrated and embedded in methylmethacrylate (MMA). Four-mm-thick sections of the distal femoral metaphysis were cut using a Microm HM360 microtome with a tungsten carbide knife. Sections were stained with Kossa/McNeal and for tartrate resistant acid phosphatase (TRACP) enzyme activity according to standard protocols. For fluorochrome analysis, undeplasticized and unstained sections were mounted with Fluoromount (Serva, Heidelberg, Germany). For cortical histomorphometry, the left femur was embedded in MMA. 200-mmthick cross sections of the femur shaft were taken using a precision band saw (Exakt, Norderstedt, Germany). The sections were subsequently ground to a final thickness of 20 mm with a microgrinding system (Exakt), and surface-stained with toluidine blue or left unstained for dynamic histomorphometry. Semiautomatic and automatic image analyses were performed using OsteoMeasure 3.0 (OsteoMetrics, Decatur, GA, USA) and AxioVision 4.6 (C. Zeiss, Jena, Germany) software, respectively. The area within 0.25 mm from the growth plates was excluded from the measurements in the distal femurs.
Biochemical bone markers
Serum osteocalcin levels were measured by EIA (Mouse Osteocalcin ELISA kit, Immutopics). Total urinary excretion of the collagen crosslink deoxypyridinoline was measured by EIA (MicroVue DPD EIA kit, Quidel), and expressed per urinary creatinine concentration. Urinary creatinine was analyzed with a Cobas c111 autoanalyzer (Roche Diagnostics).
Laser capture microdissection (LCM)
LCM will be described in detail elsewhere (Streicher et al., unpublished) . In brief, 4-mm-thick cryosections of distal femurs snapfrozen in liquid nitrogen with OCT compound (Sakura Finetek, Zoeterwoude, Netherlands) were cut on a cryotome (Leica Kryostat 1720), using the cryotape method as described (Hong et al., 2012) .
Cryosections were quickly stained with HistoStain (Arcturus). Osteoblasts (~200 cells per sample) in the cancellous bone of the distal femoral metaphysis were dissected based on their typical morphology, using a Veritas (Arcturus) laser capture microdissection system.
Quantitative real-time RT-PCR
Total RNA of the LCM-harvested osteoblasts was extracted using the SPLIT RNA Extraction Kit (Lexogen). RNA quality was determined by Agilent RNA 6000 Pico Chip (Agilent Technologies). cDNA synthesis was performed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time PCRs were performed on the Viia7 (Applied Biosystems) using the 5Â HOT FIREPol ® EvaGreen ® qPCR Mix Plus (Solis Biodyne). Primer sequences are available on request. Primer dimerization and unspecific amplification were excluded by amplicon melting analysis. N-fold change in gene expression was calculated by relative quantification. The endogenous reference gene Gapdh and the mean expression of the gene of interest in control mice were used for normalization.
Statistical analyses
Statistical analyses of the data were performed with SPSS for Windows 17.0 (SPSS Inc., Chicago, USA). Individual differences between the groups were analyzed by t-test (two groups) or one-way ANOVA followed by Student-Newman-Keuls test as post hoc test (more than two groups). In addition, the data were analyzed by 2-way ANOVA, assessing the individual effects of PTH treatment and of Areg deficiency, as well as their 2-way interaction. The graphs were generated using GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, USA). P values less than 0.05 were considered significant. The data are presented as mean ± SEM.
Results
Bone phenotype of AREG knockout mice
A previous mCT-based study reported reduced trabecular bone in 4-week-old female AREG-KO mice compared to their control littermates, but lack of changes in the cortical bone compartment (Qin et al., 2005) . To initially examine whether AREG-KO mice might show preexistent changes in bone mass or structure, we analyzed femurs from 3-and 8-month-old female mice by mCT.
Similar to earlier reports (Luetteke et al., 1999) , AREG-KO mice did not show any differences in growth or body weight (data not shown). AREG-KO mice had a slightly reduced cortical BMD at the age of 3 months and showed minor cortical thinning at the age of 8 months (Fig. 1A) in the femoral midshaft. However, no changes were observed in cancellous bone mass or structure in the distal femoral metaphysis of 3-and 8-month-old female AREG-KO mice, relative to WT controls (Fig. 1B) . Taken together, these results show that Areg deficiency does not lead to cancellous bone osteopenia, and is not associated with major detrimental effects on cortical bone in sexually mature female mice.
To determine whether ablation of AREG led to counterregulatory increases in other EGFR ligands in osteoblasts in vivo,
we assessed the mRNA abundance of all EGFR ligands by qRT-PCR in osteoblasts in the distal femoral metaphysis of male and female 3-week-old WT, heterozygous and AREG-KO mice, employing a novel laser capture microdissection technology recently developed in our laboratory (Streicher et al., unpublished) . The data from WT and heterozygous mice were combined, because there were no differences between the expression of any EGFR ligand in WT and Areg þ/ À mice (data not shown). While epiregulin (Ereg) mRNA expression remained unchanged, epidermal growth factor (Egf) and heparinbinding EGF-like growth factor (Hbegf) were upregulated in osteoblasts of AREG-KO mice (Fig. 2) . A similar trend was found for transforming growth factor-alpha (Tgfa) (P ¼ 0.062). In contrast, betacellulin (Btc) and epigen (Epgn) mRNA abundance was downregulated in osteoblasts of AREG-KO mice (Fig. 2) .
Lack of AREG does not impair the bone anabolic effect of intermittent PTH treatment
To evaluate the role of AREG in mediating the bone anabolic effect of intermittent PTH, 3-month-old female AREG-KO mice and their control littermates received daily injections of PTH or saline for a period of four weeks. Microground histological sections of the femoral midshaft revealed pronounced cortical thickening in PTHtreated AREG-KO and WT mice as compared to vehicle-treated controls (Fig. 3A) . In agreement with the data shown in Fig. 1A , 3-month-old AREG-KO mice were characterized by minor reductions in cortical BMD and thickness as evidenced by m-CT analysis (Fig. 3B) . However, intermittent PTH treatment led to comparable increases in BMD and cortical thickness in the femoral midshaft of WT and AREG-KO mice (Fig. 3B) . Fluorescence microscopy pictures of cortical bone cross-sections showed that PTH profoundly increased the amount of newly formed periosteal and endocortical bone over the whole duration of the experiment, as evidenced by the distance of the alizarin label (red line) given at the start of the experiment to the periosteal and endosteal bone surface, respectively (Fig. 3C) . Quantification of the periosteal and endocortical mineral apposition rates by bone histomorphometry showed a pronounced increase in periosteal and endocortical bone formation over the 4-week experiment period in WT and AREG-KO mice (Fig. 3C) , confirming the anabolic effect of intermittent PTH. Two-way ANOVA showed no interaction between genotype and treatment, revealing that the ability of PTH to increase cortical bone Fig. 2 . mRNA expression of EGFR ligands in femoral cancellous bone osteoblasts. Osteoblastic mRNA expression of Areg, epidermal growth factor (Egf), betacellulin (Btc), transforming growth factor alpha (Tgfa), epigen (Epgn), heparin-binding EGF-like growth factor (Hbegf), and epiregulin (Ereg) assessed by quantitative RT-PCR in 3-week-old male and female WT, heterozygous (Het), and AREG-KO mice. Osteoblasts in distal femoral cancellous bone were harvested from cryosections of femurs by laser capture microdissection. Data from WT and Het mice were combined. Data are means þ SEM of 3e6 animals/group. * denotes P < 0.01 vs. WT þ Het by t-test. The area between the red alizarine complexone line (given at the start of the experiment) and the periosteum is where the new periosteal bone has been formed. The area between the red line and the endosteum is where the new endocortical bone has been formed. Graphs show periosteal and endocortical mineral apposition rate over the whole 4-week experimental period. Data are means ± SEM of 13e14 animals/group. * denotes P < 0.01 vs. the respective vehicle-treated group or the indicated groups by 1-way ANOVA followed by SNK test. Results of 2-way ANOVA are shown below the graphs.
formation is maintained in the AREG-KO background.
Longitudinal histological sections of distal femurs clearly demonstrated the anabolic effect of intermittent PTH on cancellous and cortical bone in both WT and AREG-KO mice as compared to the saline-treated mice (Fig. 4A ). There were no differences in cancellous bone morphology or turnover between vehicle-treated WT and AREG-KO mice (Fig. 4AeC) . The PTH treatment-induced thickening of the mostly rod-like cancellous bone structures in the distal femoral metaphysis of WT and AREG-KO mice was also evident from mCT images (Fig. 4B) . m-CT analysis confirmed higher BMD, bone volume and trabecular thickness in the distal femoral metaphysis of PTH-treated WT and AREG-KO mice (Fig. 4B ). In line with the effects of PTH on bone mass and structure, bone histomorphometry showed similar PTH-induced increases in distal femoral cancellous bone formation rate in WT and AREG-KO mice (Fig. 4C) . Although the number of osteoclasts per tissue area was higher in PTH-treated WT and AREG-KO mice compared to vehicletreated controls (Fig. 4C) , the osteoclast number per bone perimeter was lower in the PTH-treated AREG-KO mice as compared to the PTH-treated WT mice (Fig. 4C) . Nevertheless, the slightly lower osteoclast numbers in the presence of similar increases in bone formation rate did not translate into a stronger anabolic effect of intermittent PTH in AREG-KO mice, relative to WT controls. With the exception of osteoclast number per bone perimeter, we found no interaction between genotype and PTH treatment, confirming the lack of a modulatory effect of AREG on the anabolic effect of PTH on cancellous bone.
Finally, to assess bone formation and bone resorption at the whole body level, we measured serum levels of osteocalcin, a systemic marker of bone formation, and urinary excretion of the collagen crosslink deoxypyridinoline, a marker of bone resorption. We found that serum osteocalcin was increased to a similar extent in PTH-treated WT and AREG-KO mice, thereby further confirming that the anabolic effect of intermittent PTH is independent of AREG not only at the local level in the femur, but also at the whole body level (Fig. 5) . Urinary deoxypyridinoline excretion remained unchanged in PTH-treated WT and AREG-KO mice, suggesting that intermittent PTH did not change whole-body bone resorption (Fig. 5) .
Discussion
The aim of the current study was to explore the role of AREG for the bone anabolic actions of PTH, employing global AREG-KO mice in which Areg exons 3 and 4 are replaced by a neomycin resistance cassette (Luetteke et al., 1999) . Earlier studies identified AREG as a PTH-regulated gene in vitro and in vivo (Qin et al., 2003 (Qin et al., , 2005 . In addition, it has been shown that PTH-mediated release of AREG in osteoblastic cells promotes migration of mesenchymal progenitors to the bone surface through PI3K/Akt and p38MAPK pathways (Zhu et al., 2012) . However, the anabolic actions of intermittent PTH on cancellous and cortical bone were comparable in 3-month-old female WT and AREG-KO mice in the present study, suggesting that the bone anabolic actions of intermittent PTH are independent of AREG.
It was previously reported that the anabolic effect of PTH was blunted in mice with impaired EGFR activity in osteoblasts (Zhu et al., 2012) . Moreover, AREG is considered the most relevant EGFR ligand in bone (Qin et al., 2003 (Qin et al., , 2005 . A possible explanation for our finding that AREG is not essential for PTH's anabolic actions is that other pathways and growth factors might compensate for the lack of AREG. For example, microarray analysis identified TGFA, another ligand of the EGFR, as a PTH-regulated gene (Qin et al., 2003) . It is conceivable that in the absence of AREG, TGFA (or other EGFR ligands) can mediate the bone anabolic effect of PTH via the EGFR. The complex changes in mRNA abundance of other EGFR ligands that we observed in osteoblasts of AREG-KO mice in this study may indirectly support this notion.
Mice lacking AREG were reported to have less trabecular bone compared to their control littermates at an age of 4 weeks (Qin et al., 2005) . However, the role of AREG in bone development and homeostasis in vivo has never been evaluated in detail. Our study indicated that AREG deficiency is not associated with cancellous bone osteopenia or changes in cancellous bone turnover in the distal femur of sexually mature, 3-to 8-month-old female mice. However, AREG-KO mice were characterized by small reductions in BMD and by mild cortical thinning at the femoral midshaft in comparison with WT controls. Collectively, our data suggest that AREG does not have a major role in the maintenance of skeletal integrity in non-growing mice. An interesting observation in this context was that cancellous bone osteoblasts harvested from the distal femora of 3-week-old AREG-KO mice by LCM showed an increased abundance of Egf and Hbegf transcripts, and a nonsignificant trend towards increased mRNA expression of Tgfa, relative to WT and heterozygous control mice. Although the role of the observed downregulation in Btc and Epgn mRNA abundance in osteoblasts of AREG-KO mice remains unclear, the counterregulatory changes in Egf and Hbegf mRNA abundance may at least partially explain the only mild skeletal phenotype of AREG-KO mice.
Although the overall anabolic effect on cancellous bone did not differ between WT and AREG-KO mice, the PTH-induced increase in osteoclast numbers was lower in PTH-treated AREG-KO mice as compared to WT controls, suggesting that the absence of AREG leads to a reduced stimulation of osteoclast recruitment by intermittent PTH. This observation is in line with previous studies showing that EGFR-like ligands can indirectly regulate osteoclastogenesis via modulating the expression levels of osteoclast regulatory factors in osteoblasts (Zhu et al., 2007) .
In conclusion, we found that AREG is dispensable for the anabolic actions of intermittent PTH on cancellous and cortical bone in 3-month-old female mice under physiological conditions. However, we cannot rule out that AREG might gain importance for mediating the bone anabolic actions of intermittent PTH under pathological conditions such as nutritional deficiencies or agerelated changes in bone metabolism. To improve our understanding of the molecular mechanisms involved in the bone anabolic actions of intermittent PTH, future work needs to assess the relevance of signaling through the two main EGF receptors in osteoblasts, EGFR and ERBB2, alone or in combination, for the bone anabolism induced by intermittent PTH.
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